MedTrace Logo

Exploring Biomarkers for Depression

NCT01424111 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2018-05-01

No results posted yet for this study

Summary

The purpose of this research is to explore objective biomarkers in voice, physiological, motor, and brain imaging signals that may one day be used to complement clinical evaluation and treatment of depression.

Conditions

Interventions

DRUG

Escitalopram

An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.

OTHER

Healthy Control

No Treatment

Sponsors & Collaborators

  • Massachusetts General Hospital

    collaborator OTHER

  • Martinos Center for Biomedical Imaging

    collaborator OTHER

  • Massachusetts Institute of Technology

    collaborator OTHER

  • Wyss Institute at Harvard University

    lead OTHER

Principal Investigators

  • Andrew Nierenberg, MD · DCRP, Massachusetts General Hospital

  • Diana Young, Ph.D · Wyss Institute, Harvard University

  • Tommi Raij, MD, Ph.D · Martinos Center, Massachusetts General Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2017-10-14
Completion
2017-10-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01424111 on ClinicalTrials.gov